title: Serial measurements of high sensitive cardiac troponin I in patients with acutely decompensated heart failure treated with carperitide or nitrates.
abstract: BACKGROUND
  In patients with acutely decompensated heart failure (ADHF), elevated serum concentration of cardiac troponin is an independent predictor of adverse cardiac events. In ADHF with a preserved systolic blood pressure, treatment with intravenous vasodilator is recommended. However, the effect of vasodilators on troponin concentrations has not been elucidated well.
  
  
  RESULTS
  Serial high sensitive cardiac troponin I (hs-TnI) was measured in 36 patients presenting with ADHF and preserved systolic blood pressure, of whom 20 were treated with atrial natriuretic peptide (ANP) and 16 with nitrates. The concentrations of hs-TnI ranged from 0.069+/-0.114ng/ml at baseline to 0.076+/-0.121ng/ml at 5h, 0.062+/-0.106ng/ml at 1 day, and 0.056+/-0.089ng/ml at day 7 (n=36,ns). The relative change in hs-TnI between baseline and at 5h, day 1 and day 7 were 1.13+/-0.43, 0.95+/-0.44 and 0.93+/-0.64 in patients treated with ANP, and 1.02+/-0.19, 0.95+/-0.31 and 1.19+/-1.38 in patients treated with nitrates (ns; ANP versus nitrates). On day 7, a hs-TnI change, >20% decrease from baseline, was observed in 55% patients with ANP versus 56% patients with nitrates (ns). The cardiac event rates were similar in both groups.
  
  
  CONCLUSIONS
  In ADHF patients with preserved systolic blood pressure, the administration of intravenous vasodilators did not decrease hs-TnI over the first 7 days. Treatments with ANP and nitrates were associated with similar short-term decreases in hs-TnI and long-term adverse cardiac events.
authors.affiliation: Department of Cardiology, Hyogo Prefectural Amagasaki Hospital, Higashidaimotsucho 1-1-1, Amagasaki, Hyogo 660-0828, Japan. cardioys@kuhp.kyoto-u.ac.jp
authors.forename: Yukihito
authors.initials: Y
authors.lastname: Sato
authors.forename: Kiyoto
authors.initials: K
authors.lastname: Nishi
authors.forename: Sayaka
authors.initials: S
authors.lastname: Saijo
authors.forename: Yohei
authors.initials: Y
authors.lastname: Tanada
authors.forename: Taisuke
authors.initials: T
authors.lastname: Goto
authors.forename: Naoki
authors.initials: N
authors.lastname: Takahashi
authors.forename: Erika
authors.initials: E
authors.lastname: Yamamoto
authors.forename: Rei
authors.initials: R
authors.lastname: Fukuhara
authors.forename: Tadashi
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Ryoji
authors.initials: R
authors.lastname: Taniguchi
authors.forename: Hisayoshi
authors.initials: H
authors.lastname: Fujiwara
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Takatsu
mesh_terms: D000368:Aged; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000627:therapeutic use*; D001794:Blood Pressure; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008297:Male; D009566:Nitrates / Q000627:therapeutic use*; D019210:Troponin I / Q000097:blood*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: C472955:NPPA protein, human; D009566:Nitrates; D019210:Troponin I; D014665:Vasodilator Agents; D009320:Atrial Natriuretic Factor